Gemcitabine and Cisplatin for Patients with Metastatic or Recurrent Esophageal Carcinoma: A Southwest Oncology Group Study
- 1 January 2004
- journal article
- clinical trial
- Published by Springer Nature in Investigational New Drugs
- Vol. 22 (1), 91-97
- https://doi.org/10.1023/b:drug.0000006179.20974.af
Abstract
Purpose: Experimental data, both in vivo and in vitro, suggest that the combination of gemcitabine and cisplatin acts synergistically. Within the Southwest Oncology Group, we designed a Phase II trial to test this chemotherapy combination for patients with esophageal cancer. Experimental design: Patients with metastatic or recurrent esophageal cancer were treated with gemcitabine 1000 mg/m2 on days 1, 8, and 15, and cisplatin 100 mg/m2 on day 15. Cycles were repeated every 28 days. The statistical endpoint was overall survival. Results: Sixty-four eligible patients were accrued from 37 institutions. Twenty-six percent of patients had prior chemotherapy. The treatment was generally well-tolerated, with the most common toxicity being neutropenia in 31% of patients. All 64 patients have died. Survival at 3 months was 81%, and at 1 year was 20%. Median survival was 7.3 months. Conclusions: This regimen is tolerable palliative option for patients with metastatic esophageal cancer.Keywords
This publication has 18 references indexed in Scilit:
- Phase II trial of docetaxel chemotherapy in patients with incurable adenocarcinoma of the esophagus.Investigational New Drugs, 2002
- A phase II trial of paclitaxel and cisplatin in patients with advanced carcinoma of the esophagus.2000
- Phase II trial of gemcitabine in patients with previously untreated metastatic cancer of the esophagus or gastroesophageal junctionAnnals of Oncology, 2000
- Phase I Study of Paclitaxel and Day 1/Day 8 Gemcitabine in Patients With Solid MalignanciesAmerican Journal of Clinical Oncology, 2000
- A Phase II Trial of Topotecan in Esophageal Carcinoma: A Southwest Oncology Group Study (SWOG 9339)Investigational New Drugs, 2000
- Phase II Trial of Weekly Irinotecan Plus Cisplatin in Advanced Esophageal CancerJournal of Clinical Oncology, 1999
- Phase I study of a biweekly schedule of a fixed dose of cisplatin with increasing doses of paclitaxel in patients with advanced oesophageal cancerBritish Journal of Cancer, 1999
- Activity of Taxol in Patients With Squamous Cell Carcinoma and Adenocarcinoma of the EsophagusJNCI Journal of the National Cancer Institute, 1994
- The Use of Mitomycin in Esophageal CancerOncology, 1993
- Studies on the mechanism of the synergistic interaction between 2?-deoxy-5-azacytidine and cisplatinCancer Chemotherapy and Pharmacology, 1992